Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study

Christoph Kern, 1, 2 Johannes Schiefelbein, 1 Dun Jack Fu, 2 Benedikt Schworm, 1 Dawn Sim, 2 Tina Herold, 1 Siegfried Priglinger, 1 Karsten Kortuem 1, 2 1Department of Ophthalmology, University Hospital LMU, Munich, Germany; 2Moorfields Eye Hospital, London, UKCorrespondence: Christoph KernDepartm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kern C, Schiefelbein J, Fu DJ, Schworm B, Sim D, Herold T, Priglinger S, Kortuem K
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
aflibercept
diabetic macular oedema
visual acuity
central retinal thickness
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/d200caeccd7d48f880b893e742750b04
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d200caeccd7d48f880b893e742750b04
record_format dspace
spelling oai:doaj.org-article:d200caeccd7d48f880b893e742750b042021-12-02T09:57:51ZTwo Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study1177-5483https://doaj.org/article/d200caeccd7d48f880b893e742750b042020-02-01T00:00:00Zhttps://www.dovepress.com/two-year-visual-acuity-and-structural-outcomes-in-patients-with-diabet-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Christoph Kern, 1, 2 Johannes Schiefelbein, 1 Dun Jack Fu, 2 Benedikt Schworm, 1 Dawn Sim, 2 Tina Herold, 1 Siegfried Priglinger, 1 Karsten Kortuem 1, 2 1Department of Ophthalmology, University Hospital LMU, Munich, Germany; 2Moorfields Eye Hospital, London, UKCorrespondence: Christoph KernDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstraße 8, Munich 80336, GermanyTel +49 89 4400 53812Email Christoph.kern@med.uni-muenchen.dePurpose: To assess visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME).Methods: For this retrospective single-center cohort study at a tertiary referral center, we performed a data warehouse query to identify 117 treatment-naive patients (139 eyes) undergoing intravitreal treatment with aflibercept for DME between January 2014 and May 2018. Changes in best-corrected visual acuity (BCVA) values (as measured with ETDRS letters), central retinal thickness (CRT) and total macular volume (TVOL) are reported over a two-year period at various time-points.Results: The total number of injections per study eye was 5.5 ± 1.4 after one and 8.7 ± 2.2 injections after two years. Baseline visual acuity (VA) was 60.1 ± 14.5 letters. A gain of 4.8 and 9.2 letters from baseline was observed after one and two years, respectively (both p ≤ 0.01). In comparison to the mean CRT at baseline (419 ± 174 μm), a CRT decrease was observed after one and two years of treatment (298 ± 115 μm and 319 ± 119 μm, respectively; both p ≤ 0.01). Similarly, TVOL decreased from 10.12 ± 2.05 mm 3 to 8.96 ± 0.96 mm 3 and 9.01 ± 1.29 mm 3 (both p ≤ 0.01).Conclusion: This study demonstrates that treating DME with intravitreal aflibercept yields positive functional and structural outcomes over a two-year period. However, we observed fewer injection numbers, along with inferior VA and structural outcomes than has been reported in randomized clinical trials. Our results show similar results as in patients treated with ranibizumab due to DME in real-life settings.Keywords: aflibercept, diabetic macular oedema, visual acuity, central retinal thicknessKern CSchiefelbein JFu DJSchworm BSim DHerold TPriglinger SKortuem KDove Medical Pressarticleafliberceptdiabetic macular oedemavisual acuitycentral retinal thicknessOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 533-541 (2020)
institution DOAJ
collection DOAJ
language EN
topic aflibercept
diabetic macular oedema
visual acuity
central retinal thickness
Ophthalmology
RE1-994
spellingShingle aflibercept
diabetic macular oedema
visual acuity
central retinal thickness
Ophthalmology
RE1-994
Kern C
Schiefelbein J
Fu DJ
Schworm B
Sim D
Herold T
Priglinger S
Kortuem K
Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
description Christoph Kern, 1, 2 Johannes Schiefelbein, 1 Dun Jack Fu, 2 Benedikt Schworm, 1 Dawn Sim, 2 Tina Herold, 1 Siegfried Priglinger, 1 Karsten Kortuem 1, 2 1Department of Ophthalmology, University Hospital LMU, Munich, Germany; 2Moorfields Eye Hospital, London, UKCorrespondence: Christoph KernDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstraße 8, Munich 80336, GermanyTel +49 89 4400 53812Email Christoph.kern@med.uni-muenchen.dePurpose: To assess visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME).Methods: For this retrospective single-center cohort study at a tertiary referral center, we performed a data warehouse query to identify 117 treatment-naive patients (139 eyes) undergoing intravitreal treatment with aflibercept for DME between January 2014 and May 2018. Changes in best-corrected visual acuity (BCVA) values (as measured with ETDRS letters), central retinal thickness (CRT) and total macular volume (TVOL) are reported over a two-year period at various time-points.Results: The total number of injections per study eye was 5.5 ± 1.4 after one and 8.7 ± 2.2 injections after two years. Baseline visual acuity (VA) was 60.1 ± 14.5 letters. A gain of 4.8 and 9.2 letters from baseline was observed after one and two years, respectively (both p ≤ 0.01). In comparison to the mean CRT at baseline (419 ± 174 μm), a CRT decrease was observed after one and two years of treatment (298 ± 115 μm and 319 ± 119 μm, respectively; both p ≤ 0.01). Similarly, TVOL decreased from 10.12 ± 2.05 mm 3 to 8.96 ± 0.96 mm 3 and 9.01 ± 1.29 mm 3 (both p ≤ 0.01).Conclusion: This study demonstrates that treating DME with intravitreal aflibercept yields positive functional and structural outcomes over a two-year period. However, we observed fewer injection numbers, along with inferior VA and structural outcomes than has been reported in randomized clinical trials. Our results show similar results as in patients treated with ranibizumab due to DME in real-life settings.Keywords: aflibercept, diabetic macular oedema, visual acuity, central retinal thickness
format article
author Kern C
Schiefelbein J
Fu DJ
Schworm B
Sim D
Herold T
Priglinger S
Kortuem K
author_facet Kern C
Schiefelbein J
Fu DJ
Schworm B
Sim D
Herold T
Priglinger S
Kortuem K
author_sort Kern C
title Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
title_short Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
title_full Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
title_fullStr Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
title_full_unstemmed Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
title_sort two year visual acuity and structural outcomes in patients with diabetic macular oedema treated with intravitreal aflibercept – a retrospective cohort study
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/d200caeccd7d48f880b893e742750b04
work_keys_str_mv AT kernc twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT schiefelbeinj twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT fudj twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT schwormb twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT simd twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT heroldt twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT priglingers twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
AT kortuemk twoyearvisualacuityandstructuraloutcomesinpatientswithdiabeticmacularoedematreatedwithintravitrealafliberceptndasharetrospectivecohortstudy
_version_ 1718397909642248192

Ejemplares similares